Oncology

Weight Loss May Reduce Breast Cancer Risk in Postmenopausal Women

Weight Loss May Reduce Breast Cancer Risk in Postmenopausal Women

Postmenopausal women with weight loss have a reduced risk for breast cancer.

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

By

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

Higher Levels of Anti-CA15.3 and Anti-CA125 Linked to Increased Risk for Mucinous Epithelial Ovarian Cancer

Higher Levels of Anti-CA15.3 and Anti-CA125 Linked to Increased Risk for Mucinous Epithelial Ovarian Cancer

By

Researchers used the EPIC Cohort to identify whether anti-CA125 and anti-CA15.3 antibodies alone or in combination with antigens may determine epithelial ovarian cancer risk.

Better Efforts Needed for Cancer Patients With Pessimistic Illness Perceptions

Better Efforts Needed for Cancer Patients With Pessimistic Illness Perceptions

By

Among cancer survivors, illness perception may affect patient health-related quality of life and mortality.

Ovarian Cancer Risk Reduced With Regular, Low-Dose Aspirin

Ovarian Cancer Risk Reduced With Regular, Low-Dose Aspirin

By

Although ovarian cancer risk may be reduced with regular use of low-dose aspirin, the use of nonaspirin analgesics may increase the risk of ovarian cancer among long-term, high-quantity users.

Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes

Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes

Stool burden can be a particularly challenging aspect of colonoscopies, making potentially cancerous lesions easier to miss.

Weight Loss May Predict Cancer Diagnosis in Primary Care

Weight Loss May Predict Cancer Diagnosis in Primary Care

By

Weight loss may indicate a cancer diagnosis in patients presenting in primary care, specifically when weight loss correlates to another cancer-related clinical feature.

Genomic Screening Can ID Undetected <i>BRCA1/2</i> Cancer Risk

Genomic Screening Can ID Undetected BRCA1/2 Cancer Risk

82 percent of variant carriers identified in exome sequencing had not undergone prior testing.

Ketogenic Diet May Benefit Ovarian, Endometrial Cancer Patients

Ketogenic Diet May Benefit Ovarian, Endometrial Cancer Patients

By

Women with ovarian or endometrial cancer who adhere to a ketogenic diet may benefit from a selective loss of fat mass and a reduction in fasting serum insulin, while still retaining lean mass.

Second Opinion at NCI Center Valuable for Breast CA Patients

Second Opinion at NCI Center Valuable for Breast CA Patients

Almost 43% of those presenting to NCI center for second opinion have change in diagnosis.

Barriers Found in PCP Knowledge of Surveillance of Hepatocellular Carcinoma

Barriers Found in PCP Knowledge of Surveillance of Hepatocellular Carcinoma

By

Barriers found among PCPs in surveillance of HCC indicate the need for clinical interventions, including provider education.

Talazoparib Shows Antitumor Activity in Advanced Breast Cancer, Germline <i>BRCA</i> Mutation

Talazoparib Shows Antitumor Activity in Advanced Breast Cancer, Germline BRCA Mutation

By

Talazoparib, a poly(adenosine diphosphate-ribose) inhibitor, may significantly enhance progression-free survival in patients with advanced breast cancer and a germline BRCA1/2 mutation.

Newer Hormonal Contraception May Cut Ovarian Cancer Risk

Newer Hormonal Contraception May Cut Ovarian Cancer Risk

Combined hormonal contraception use tied to lower risk; risk down with increasing duration of use.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Tucatinib May Be A Safe, Novel Treatment for <i>ERBB2/HER2</i>-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

NAMS: Breast Cancer Diagnosis May Indicate Lower Vitamin D Levels, Obesity in Postmenopausal Women

NAMS: Breast Cancer Diagnosis May Indicate Lower Vitamin D Levels, Obesity in Postmenopausal Women

By

The North American Menopause Society has found that postmenopausal women with a breast cancer diagnosis may have vitamin D deficiency as well as higher rates of obesity.

Beyond <I>BRCA</i>: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

By

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Olaparib Treatment May Improve Health-Related Quality of Life in Germline <I>BRCA1/2</I>-Mutated Ovarian Cancer

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

By

Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.

PSA Testing Not Recommended for Prostate Cancer Screening

PSA Testing Not Recommended for Prostate Cancer Screening

Odds of choosing screening up for men with family history, African descent, low socioeconomic status.

Adjuvant Chemo With Endocrine Therapy for HR+/HER2- Breast Cancer

Adjuvant Chemo With Endocrine Therapy for HR+/HER2- Breast Cancer

By

Although endocrine therapy following surgery is recommended for HR-positive/HER2-negative, axillary node-negative breast cancers, the value of adjuvant chemotherapy in the setting of moderate risk is unclear.

TNFi Not Linked to Increased Cancer Recurrence in RA Patients

TNFi Not Linked to Increased Cancer Recurrence in RA Patients

No increased risk of cancer recurrence among RA patients initiating tumor necrosis factor inhibitor treatment.

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every 3 years from age 21; different screening options from age 30 to 65.

Similar Outcomes for Rural, Urban Cancer Patients in SWOG Trials

Similar Outcomes for Rural, Urban Cancer Patients in SWOG Trials

Few differences between rural, urban patients in cancer outcomes with uniform access to cancer care.

Investigational Therapy Gets Fast Track Status for Recurrent Ovarian Cancer

Investigational Therapy Gets Fast Track Status for Recurrent Ovarian Cancer

By

A Phase 1 study in healthy volunteers showed a favorable safety profile with no serious adverse events.

Lumpectomy &#43; Radiation May Cut Breast Cancer Mortality in DCIS

Lumpectomy + Radiation May Cut Breast Cancer Mortality in DCIS

Lumpectomy, radiotherapy tied to reduction in breast cancer mortality vs lumpectomy, mastectomy.

Majority of Patients With Liver Metastases From Colorectal Cancer Eligible for Laparoscopy

Majority of Patients With Liver Metastases From Colorectal Cancer Eligible for Laparoscopy

By

In high-volume centers, patients with liver metastases from colorectal cancer may often be eligible for minimally invasive liver surgery via laparoscopy, thereby reducing potential morbidity risks associated with open surgery.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

Proton Pump Inhibitor Treatment and Aspirin Improve Outcomes in Barrett Esophagus

Proton Pump Inhibitor Treatment and Aspirin Improve Outcomes in Barrett Esophagus

By

High-dose esomeprazole taken in combination with aspirin may safely and effectively improve outcomes in patients with Barrett esophagus.

Link for Asbestos-Free Talcum Powder, Cancer Not Clear

Link for Asbestos-Free Talcum Powder, Cancer Not Clear

Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer.

FDA Grants First Approval for CA Drug Under New Pilot Programs

FDA Grants First Approval for CA Drug Under New Pilot Programs

Ribociclib approved in combo with AI as endocrine tx for HR-positive, HER2-negative advanced breast CA.

Sign Up for Free e-newsletters